SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-031095
Filing Date
2022-11-30
Accepted
2022-11-30 16:46:45
Documents
14
Period of Report
2022-11-30
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nltx-20221130.htm   iXBRL 8-K 41961
2 EX-3.1 neoleukin-amendedandrestat.htm EX-3.1 238309
  Complete submission text file 0001628280-22-031095.txt   476493

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nltx-20221130.xsd EX-101.SCH 2216
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nltx-20221130_def.xml EX-101.DEF 2986
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nltx-20221130_lab.xml EX-101.LAB 27182
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nltx-20221130_pre.xml EX-101.PRE 14210
8 EXTRACTED XBRL INSTANCE DOCUMENT nltx-20221130_htm.xml XML 11073
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 221436092
SIC: 2834 Pharmaceutical Preparations